Business Context and Reporting Period
This Form 8-K was filed by Integrity Applications, Inc. (not Glucotrack, Inc., as noted in the metadata) on March 18, 2013, reporting events occurring on March 12 and March 13, 2013. The Company is a Delaware corporation headquartered in Ashkelon, Israel, focused on medical device manufacturing.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company received aggregate proceeds of $6,300,000 from the sale of 6,300 Units.
- Instrument Details: Each Unit consists of one share of Series A 5% Convertible Preferred Stock (stated value $1,000) and one warrant to purchase common stock.
- Conversion Terms: Preferred Stock converts to common stock at an initial price of $5.80 per share. Warrants are exercisable at $6.96 per share.
- Dilution Potential: The Preferred Stock is convertible into an aggregate of 1,086,206 shares of Common Stock. The Warrants are exercisable for an aggregate of 1,086,206 shares of Common Stock.
- Dividend Obligation: Preferred Stockholders are entitled to cumulative dividends at 5% per annum, payable quarterly. Late fees of 9% per annum apply to unpaid dividends.
- Transaction Costs: The Company paid a placement agent commission equal to 7% of the aggregate sales price, plus a 3% management fee and a 3% expense allowance.
Material Changes and Agreements
The filing details the entry into a Material Definitive Agreement (Securities Purchase Agreement) and the issuance of unregistered equity securities. This transaction represents the second and final closing of a private placement offering. Additionally, the Company amended its Certificate of Incorporation to designate the Series A Preferred Stock.
Significant modifications to prior securities include:
- First Closing Exchange: Shares of Common Stock sold in November 2012 at $7.00 per share are being exchanged for Units in this offering.
- Price Adjustment for Prior Investors: The Company agreed to issue additional shares to holders of Common Stock issued between 2010 and 2011 to reduce their effective purchase price from $6.25 to $5.80 per share.
Outlook, Risks, and Other Events
- ISO Certification: On March 13, 2013, the Company received ISO 13485:2003 quality system certification from DEKRA Certification B.V. This certifies compliance with quality management standards for medical devices but does not guarantee CE Mark approval.
- Trading Status: While shares are eligible for DTC clearing, there has been no reported sale or posted bid/ask price on the OTC Bulletin Board since approval. A priced quotation is not guaranteed.
- Registration Rights: The Company must file a registration statement within 45 days for the resale of conversion shares and warrant shares. Failure to do so triggers partial liquidated damages of 2% of the purchase price.
- Risks: The filing references risks regarding the timely receipt of CE Mark approval for the GlucoTrack DF-F glucose monitoring device. The Company faces potential redemption obligations upon material breach, change in control, or insolvency.
Investor Verification Checklist
- Verify the Company's actual name is Integrity Applications, Inc., not Glucotrack, Inc.
- Confirm the status of the registration statement filing required within 45 days of March 13, 2013.
- Assess the liquidity of the Common Stock given the lack of reported sales or bid/ask prices on the OTC Bulletin Board.
- Review the Company's progress toward CE Mark approval for its medical devices, as ISO certification alone is insufficient for market entry in Europe.
- Monitor the Company's ability to meet quarterly cash dividend obligations on the Preferred Stock to avoid 9% late fees.